LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
- Written by PR Newswire
First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseases
SEOUL, South Korea, Dec. 8, 2022 /PRNewswire/ -- LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA.
On December 1,...
Read more: LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
